GO
Loading...

BRIEF-Vertex to present mid-stage study data of experimental fibrosis drug

Thursday, 11 Oct 2012 | 9:01 AM ET

Oct 11 (Reuters) - Vertex Pharmaceuticals Inc :

* Data from phase 2 combination study of vx-809 and ivacaftor in people with

cystic fibrosis who have the most common genetic mutation (f508del) presented

at North American cystic fibrosis conference

* Source text * Further company coverage

((Bangalore Newsroom; +1 646 223 8780))

  Price   Change %Change
VRTX
---